On January 3, 2024, Eli Lilly and Company announced LillyDirect™, a digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect™ offers a pharmacy fulfillment solution, disease state management and educational resources, access to telehealth providers, as well as, a search tool for local healthcare professionals. There are 14 drugs available through LillyDirect™ including Basaglar, Lyumjev, Rezvoglar, and multiple formulations of Humalog and Humulin. Patients can also access Zepbound for chronic weight management, but Mounjaro for type 2 diabetes is not currently offered. Emgality for migraine is also available on the platform. Some healthcare experts worry offering medications direct from the drug manufacturer may make it easier for pharmaceutical companies to target consumers, regardless of whether the medication is the appropriate treatment for the patient. Other drug manufacturers, especially those with chronic weight management medications, will most likely follow suite as they look for ways to get their medications to more patients.
